Warning! GuruFocus detected
2 Severe warning signs
with INM.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
InMed Pharmaceuticals Inc
NAICS : 325412
SIC : 3741
ISIN : CA4576371062
Description
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.6 | |||||
| Equity-to-Asset | 0.73 | |||||
| Debt-to-Equity | 0.15 | |||||
| Debt-to-EBITDA | -0.13 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -19.63 | |||||
| Beneish M-Score | -3.01 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 70.1 | |||||
| 3-Year EPS without NRI Growth Rate | 70.3 | |||||
| 3-Year FCF Growth Rate | 71 | |||||
| 3-Year Book Growth Rate | -64.5 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 50.39 | |||||
| 9-Day RSI | 46.77 | |||||
| 14-Day RSI | 43.13 | |||||
| 3-1 Month Momentum % | -29.07 | |||||
| 6-1 Month Momentum % | -41.11 | |||||
| 12-1 Month Momentum % | -57.64 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.05 | |||||
| Quick Ratio | 2.44 | |||||
| Cash Ratio | 1.91 | |||||
| Days Inventory | 128.66 | |||||
| Days Sales Outstanding | 22.38 | |||||
| Days Payable | 55.12 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -203.2 | |||||
| Shareholder Yield % | -38.01 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 35.36 | |||||
| Operating Margin % | -160.67 | |||||
| Net Margin % | -163.75 | |||||
| FCF Margin % | -150.88 | |||||
| ROE % | -83.03 | |||||
| ROA % | -66.61 | |||||
| ROIC % | -177.64 | |||||
| 3-Year ROIIC % | 104.34 | |||||
| ROC (Joel Greenblatt) % | -362.16 | |||||
| ROCE % | -76.3 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.32 | |||||
| PB Ratio | 0.33 | |||||
| Price-to-Tangible-Book | 0.45 | |||||
| EV-to-EBIT | -0.12 | |||||
| EV-to-EBITDA | -0.13 | |||||
| EV-to-Revenue | 0.19 | |||||
| EV-to-Forward-Revenue | 0.01 | |||||
| EV-to-FCF | -0.13 | |||||
| Price-to-GF-Value | 0.55 | |||||
| Price-to-Net-Current-Asset-Value | 0.64 | |||||
| Price-to-Net-Cash | 1.83 | |||||
| Earnings Yield (Greenblatt) % | -833.33 | |||||
| FCF Yield % | -217.28 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:INM
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
InMed Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 4.833 | ||
| EPS (TTM) ($) | -13.75 | ||
| Beta | 0.27 | ||
| 3-Year Sharpe Ratio | -1.35 | ||
| 3-Year Sortino Ratio | -1.65 | ||
| Volatility % | 130.55 | ||
| 14-Day RSI | 43.13 | ||
| 14-Day ATR ($) | 0.220728 | ||
| 20-Day SMA ($) | 2.78 | ||
| 12-1 Month Momentum % | -57.64 | ||
| 52-Week Range ($) | 2.414 - 15.696 | ||
| Shares Outstanding (Mil) | 1.21 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
InMed Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
InMed Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
InMed Pharmaceuticals Inc Frequently Asked Questions
What is InMed Pharmaceuticals Inc(INM)'s stock price today?
The current price of INM is $2.78. The 52 week high of INM is $15.70 and 52 week low is $2.41.
When is next earnings date of InMed Pharmaceuticals Inc(INM)?
The next earnings date of InMed Pharmaceuticals Inc(INM) is 2025-05-14 Est..
Does InMed Pharmaceuticals Inc(INM) pay dividends? If so, how much?
InMed Pharmaceuticals Inc(INM) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers